Close
Smartlab Europe
Achema middle east

Purdue Pharma announces availability of insomnia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...
- Advertisement -

Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep.

Intermezzo (zolpidem tartrate), which contains a bicarbonate-carbonate buffer, is available in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. The product is available on prescription in retail pharmacies in the US, the company said.

Purdue Pharma president and CEO John Stewart said: “We are confident that healthcare professionals will find Intermezzo to be a valuable therapeutic option.”

Latest stories

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »